



Moxeza[®] (moxifloxacin) – First-time generic

- On February 14, 2020, [Lupin launched](#) an [AT-rated](#) generic version of Alcon's [Moxeza \(moxifloxacin\)](#) 0.5% ophthalmic solution.
- Moxeza is approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
- Moxifloxacin ophthalmic is also available as a generic [0.5% ophthalmic solution](#) (Vigamox[®]) approved to treat bacterial conjunctivitis caused by susceptible strains of organisms.
- Moxeza had sales of approximately \$10 million in the U.S. according to IQVIA for the 12 months ending December 2019.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.